Trials / Unknown
UnknownNCT02939274
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Rogers Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verteporfin | |
| DEVICE | Continuous Low-Irradiance Photodynamic Therapy (CLIPT) |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2016-10-20
- Last updated
- 2018-07-20
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02939274. Inclusion in this directory is not an endorsement.